Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

Supplementary Figure 1 from Preclinical Study of a Biparatopic METxMET Antibody–Drug Conjugate, REGN5093-M114, Overcomes MET-driven Acquired Resistance to EGFR TKIs in EGFR-mutant NSCLC

<p>Genomic landscape in patient-derived preclinical models. The genetic alteration of the PDC (patient-derived cell), PDO (patient-derived organoid), and PDX (patient-derived xenograft) models are shown as an oncoprint plot.</p>

שמור ב:
מידע ביבליוגרפי
מחבר ראשי: Seung Yeon Oh (15051017) (author)
מחברים אחרים: You Won Lee (15051020) (author), Eun Ji Lee (15051023) (author), Jae Hwan Kim (15051026) (author), YoungJoon Park (15051029) (author), Seong Gu Heo (15032490) (author), Mi Ra Yu (15051032) (author), Min Hee Hong (15014541) (author), John DaSilva (15051035) (author), Christopher Daly (15030374) (author), Byoung Chul Cho (15032496) (author), Sun Min Lim (15051038) (author), Mi Ran Yun (15032484) (author)
יצא לאור: 2025
נושאים:
Cancer
Therapeutic Research and Development
Drug Resistance
Clinical drug resistance
Lung Cancer
Translational Research
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
היה/י הראשונ/ה לכתוב הערה!
צריך להיות מחובר מראש

פריטים דומים